Hib-DTaP-hepatitis B-poliovirus vaccine - sanofi pasteur MSD

Drug Profile

Hib-DTaP-hepatitis B-poliovirus vaccine - sanofi pasteur MSD

Alternative Names: AR21; DTaP2-HepB-Polio-Hib - sanofi pasteur MSD; Hexavac

Latest Information Update: 25 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi pasteur MSD
  • Class Haemophilus vaccines; Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Market Withdrawal Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus

Most Recent Events

  • 20 Sep 2005 The CHMP has recommended the suspension of Hexavac® due to concerns regarding the long-term protection against hepatitis B
  • 24 Feb 2005 The CHMP is reviewing the safety of Hexavac®
  • 19 Jan 2005 Aventis Pasteur MSD is now called sanofi pasteur MSD
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top